Elsevier

Neurobiology of Disease

Volume 25, Issue 2, February 2007, Pages 412-426
Neurobiology of Disease

Neuroprotective effects of erythropoietin in the rat hippocampus after pilocarpine-induced status epilepticus

https://doi.org/10.1016/j.nbd.2006.10.009Get rights and content

Abstract

Neuroprotective functions of erythropoietin (Epo) are thought to involve a heteroreceptor composed of both Epo receptor (Epo-R) and common β chain (βc). Here, we measured the response of hippocampal Epo system components (Epo, Epo-R and βc) during neurodegenerative processes following pilocarpine-induced status epilepticus (SE), and examined whether recombinant human Epo (rHuEpo) could support neuronal survival. We evidence that Epo is induced in astroglia following SE, in particular within areas displaying delayed neuronal death. In addition, we demonstrate for the first time that rHuEpo reduces considerably hippocampal neurodegeneration following SE. rHuEpo may thus supplement astroglial induction of Epo to promote enhanced hippocampal neuronal survival following SE. We also show that Epo-R is expressed by neurons and astrocytes mainly, while βc is barely detectable in basal conditions and induced in reactive microglia exclusively following SE. Altogether, our results suggest that Epo/rHuEpo exerts neuroprotection, through Epo-R signaling and independently of βc, and, therefore, may be anti-epileptogenic.

Introduction

Erythropoietin (Epo) was originally described for its role in hematopoiesis, which consists of increasing red blood cells (Jelkmann, 1992) by protecting erythroid progenitors against apoptosis (Ghezzi and Brines, 2004). Epo and its receptor (Epo-R) are expressed in rodent and human brain, in cultured neurons, astrocytes, oligodendrocytes, microglia, and endothelial cells (Marti et al., 1996, Juul et al., 1999, Chin et al., 2000, Siren et al., 2001, Hasselblatt et al., 2006), which has led to studies of additional biological roles of Epo. Exogenous administration of Epo revealed neuroprotective activity in vitro and in vivo in models of central and peripheral neuronal injury occurring in the contexts of trauma, stroke and inflammation (Juul et al., 2004, Campana and Myers, 2003, Maiese et al., 2004, Brines and Cerami, 2005).

Recombinant human Epo (rHuEpo)-administered peripherally crosses the blood–brain barrier (BBB) (Brines et al., 2000, Ehrenreich et al., 2004, Juul et al., 2004, Gorio et al., 2005). Studies in rodent models of temporal lobe epilepsy (TLE) revealed significant effects of rHuEpo in antagonizing the development of status epilepticus (SE), but did not determine whether rHuEpo was neuroprotective (Brines et al., 2000, Uzum et al., 2006). Interestingly, many of the programmed cell death pathways involved in animal models of TLE (Henshall and Simon, 2005) are those targeted by Epo (Maiese et al., 2004, Brines and Cerami, 2005).

Possible adverse effects of rHuEpo, such as increase in blood pressure, thrombosis, tumor expansion, and mortality (Maiese et al., 2004, Brines and Cerami, 2005) have spurred the development of Epo derivatives that are neuroprotective, but not erythropoietic (Leist et al., 2004). Carbamylated Epo (CEPO), which is one such derivatives, has a low affinity for Epo-R homodimer compared to native Epo, and is neuroprotective in vivo in the neocortex (Leist et al., 2004) and the spinal cord (Brines et al., 2004, Leist et al., 2004). Although it has been suggested that Epo-mediated neuroprotection occurs via Epo-R homodimers (Maiese et al., 2005), CEPO- and rHuEpo-mediated neuroprotection in the spinal cord may involve a heteroreceptor complex, consisting of a single Epo-R and a homodimer of the common β chain (βc) of the Granulocyte–Macrophage Colony-Stimulating Factor (GM-CSF), Interleukin-3 (IL-3) and IL-5 receptors, as demonstrated in âc-knockout mice, which express normal levels of Epo-R (Brines et al., 2004, Genc et al., 2004, Brines and Cerami, 2005). Thus, available data suggest that several Epo binding sites may mediate neuroprotection, either through Epo-R homodimers or Epo-R/βc heteroreceptors.

Although exogenous Epo appears to be neuroprotective, little is know about the expression patterns of Epo system constituents under basal and induced conditions. Epo system expression has been investigated after cerebral ischemia (Bernaudin et al., 1999) and traumatic injury in the spinal cord (Grasso et al., 2005) and peripheral nervous system (Campana and Myers, 2001, Li et al., 2005). However, Epo system expression has not yet been assessed after chemically-induced SE, which initiates the process of epileptogenesis (Turski et al., 1983).

In this study, we have investigated the expression of Epo system constituents (Epo, Epo-R and the βc) both in basal conditions and in response to pilocarpine-induced SE (Pilo-SE). Our results show that Epo-R is expressed constitutively by most neurons of the hippocampus, but rarely by astrocytes. Following Pilo-SE, we report the transient induction of Epo in hippocampal astrocytes and a long-lasting induction of Epo-R. We also report that constitutive expression of βc subunit is low in the hippocampus compared to the spinal cord, whereas βc subunit expression dramatically increases after Pilo-SE in reactive microglia. Finally, we demonstrate that administration of rHuEpo following Pilo-SE significantly protects hippocampal neurons, suggesting that rHuEpo may be both neuroprotective and anti-epileptogenic.

Section snippets

Procedures and methods

All animal procedures were in compliance with the guidelines of the European Union (directive 86/609), taken in the French law (decree 87/848) regulating animal experimentation. All efforts were made to minimize animal suffering and to reduce the number of animals used.

Animals

Sprague–Dawley male rats (Harlan, France) were used throughout the experiments. They arrived at 5 weeks old in approved facilities, and housed at 21 ± 1°C under diurnal lighting conditions (lights on from 06:00 to 18:00). They were maintained in groups of 5 in plastic cages with free access to food and water. After 2-week acclimatization, rats (180–200 g) underwent Pilo-SE as described below, and were then housed individually to support recovery until sacrificed. Control rats were housed in

Reverse Transcriptase real time Polymerase Chain Reaction (RT-real time PCR)

Total RNAs were extracted with Tri-reagent LS (Euromedex) and genomic DNA was removed after DNase I digestion (RNAse Free DNAse Set, Qiagen). After column purification (RNeasy kit, Qiagen) and prior to reverse transcription, total RNA from all samples were shown to be free of genomic DNA contamination by a PCR amplification of the exon V of the gene encoding brain-derived neurotrophic factor (BDNF) (see below for details). Messenger RNAs, contained in 500 ng of hippocampal total RNAs, were then

Basal expression and distribution of both Epo-R and Epo in the hippocampus

In control rats, 983 ± 133 copies of Epo-R cDNA and 224 ± 55 copies of Epo cDNA were quantified by real time PCR following reverse transcription of 500 ng of hippocampal total RNA.

Colorimetric immunolabeling showed that Epo-R was expressed in the principal cell layers of the dentate gyrus and Ammon’s horn (Fig. 1A). Dual fluorescent labeling of Epo-R together with specific markers of either neurons (NeuN), astrocytes (GFAP) or microglial cells (OX-42) demonstrated that Epo-R was expressed primarily

Discussion

The original findings of this study include description of Epo, Epo-R, and common β chain (βc) expression in the rat hippocampus under basal and induced conditions. Epo-R protein is constitutively expressed in a large majority of neurons, while Epo and βc protein expression are much more discrete, and restricted to specific neuronal populations. Few astrocytes constitutively express Epo and Epo-R in every area of the hippocampus. Following Pilo-SE, Epo and Epo-R are induced in numerous

Acknowledgments

This work was supported by grants from the Centre National de la Recherche Scientifique (CNRS) and the Université Claude Bernard Lyon 1 (UCBL1). We thank B. Smatti, D. Ressnikoff and Y. Tourneur from the Centre Commun de Quantimétrie (CCQ) of the UCBL1 for their excellent technical assistance in confocal microscopy studies.

References (63)

  • L.C. Schmued et al.

    Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration

    Brain Res.

    (2000)
  • R.S. Sloviter

    The neurobiology of temporal lobe epilepsy: too much information, not enough knowledge

    Comptes Rendus Biol.

    (2005)
  • W.A. Turski et al.

    Limbic seizures produced by pilocarpine in rats: behavioural, electroencephalographic and neuropathological study

    Behav. Brain Res.

    (1983)
  • G. Uzum et al.

    Erythropoietin prevents the increase in blood–brain barrier permeability during pentylentetrazol induced seizures

    Life Sci.

    (2006)
  • B. Voutsinos-Porche et al.

    Temporal patterns of the cerebral inflammatory response in the rat lithium-pilocarpine model of temporal lobe epilepsy

    Neurobiol. Dis.

    (2004)
  • K. Appel et al.

    Cloning of rat interleukin-3 receptor beta-subunit from cultured microglia and its mRNA expression in vivo

    J. Neurosci.

    (1995)
  • M. Bernaudin et al.

    A potential role for erythropoietin in focal permanent cerebral ischemia in mice

    J. Cereb. Blood Flow Metab.

    (1999)
  • M. Bernaudin et al.

    Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain

    Glia

    (2000)
  • M. Bernaudin et al.

    Normobaric hypoxia induces tolerance to focal permanent cerebral ischemia in association with an increased expression of hypoxia-inducible factor-1 and its target genes, erythropoietin and VEGF, in the adult mouse brain

    J. Cereb. Blood Flow Metab.

    (2002)
  • I. Blumcke et al.

    Loss of hilar mossy cells in Ammon's horn sclerosis

    Epilepsia

    (2000)
  • M. Brines et al.

    Emerging biological roles for erythropoietin in the nervous system

    Nat. Rev., Neurosci.

    (2005)
  • M.L. Brines et al.

    Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury

    Proc. Natl. Acad. Sci. U. S. A.

    (2000)
  • M. Brines et al.

    Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor

    Proc. Natl. Acad. Sci. U. S. A.

    (2004)
  • W.M. Campana et al.

    Erythropoietin and erythropoietin receptors in the peripheral nervous system: changes after nerve injury

    FASEB J.

    (2001)
  • W.M. Campana et al.

    Exogenous erythropoietin protects against dorsal root ganglion apoptosis and pain following peripheral nerve injury

    Eur. J. Neurosci.

    (2003)
  • E.A. Cavalheiro

    GAD-immunoreactive neurons are preserved in the hippocampus of rats with spontaneous recurrent seizures

    Braz. J. Med. Biol. Res.

    (1990)
  • Z.Z. Chong et al.

    Erythropoietin fosters both intrinsic and extrinsic neuronal protection through modulation of microglia, Akt1, Bad, and caspase-mediated pathways

    Br. J. Pharmacol.

    (2003)
  • M. Digicaylioglu et al.

    Localization of specific erythropoietin binding sites in defined areas of the mouse brain

    Proc. Natl. Acad. Sci. U. S. A.

    (1995)
  • H. Ehrenreich et al.

    Erythropoietin therapy for acute stroke is both safe and beneficial

    Mol. Med.

    (2002)
  • H. Ehrenreich et al.

    Erythropoietin: a candidate compound for neuroprotection in schizophrenia

    Mol. Psychiatry

    (2004)
  • H. Ehrenreich et al.

    A hematopoietic growth factor, thrombopoietin, has a proapoptotic role in the brain

    Proc. Natl. Acad. Sci. U. S. A.

    (2005)
  • Cited by (97)

    • Mutant erythropoietin enhances white matter repair via the JAK2/STAT3 and C/EBPβ pathway in middle-aged mice following cerebral ischemia and reperfusion

      2021, Experimental Neurology
      Citation Excerpt :

      Subsequently, several laboratories reported the tissue protection of EPO or EPO derivatives were mediated through the common β receptor (βCR) subunit alone, also known as CD131, or a heteroreceptor complex comprising both EPOR and βCR (Brines et al., 2004; Foley et al., 2017). In agreement with previous studies in a pilocarpine-induced status epilepticus model (Nadam et al., 2007), our colocalization data also suggest that more EPOR is expressed in neurons, while more βCR is expressed in reactive microglia at 3 days following cerebral ischemia. These results suggest that microglia may be a potential target for MEPO to exert neuroprotective effects.

    • Erythropoietin Increases GABA<inf>A</inf> Currents in Human Cortex from TLE Patients

      2020, Neuroscience
      Citation Excerpt :

      Recombinant human Epo (rHuEpo) is able to cross the blood–brain barrier (BBB) (Brines et al., 2000; Ferriero, 2005) and, when systemically delivered, it is able to reduce tissue damage in animal model of ischemic stroke (Sirén et al., 2001). Moreover, the modulatory effect of EPO on neurogenesis has been also observed in epilepsy; both endogenous and exogenous EPO have been implicated in reduction of brain damage related to generalized seizure (Nadam et al., 2007), and in a rodent model of temporal lope epilepsy (TLE), EPO showed a significant effect in antagonizing the development of status epilepticus (SE) (Uzum et al., 2006). Notably, one study (Ott et al., 2015) demonstrated that EPO-R is upregulated in some specific areas of the hippocampus obtained from surgical resection in a single patient afflicted from pharmaco-resistant complex-focal seizures of temporal-mesial origin, indicating thus a possible, not yet fully clarified, role of EPO system in focal epilepsy.

    • Carbamoylated erythropoietin induces a neurotrophic gene profile in neuronal cells

      2019, Progress in Neuro-Psychopharmacology and Biological Psychiatry
    View all citing articles on Scopus
    View full text